Company profile
Inhibrx Biosciences Inc.
NASDAQ: INBX · Healthcare · Biotechnology
PublicHQ La Jolla, CACIK 0002007919Reports USD
#849 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
28DFH 28DQ 21GM —SS 51
v0.1 · 55/100 weight · provisional
↑ revenue growth (YoY), market scale · ↓ return on equity, listing tenure
Methodology →Revenue TTM
$1.3M
Rev growth YoY (TTM)
+550.0%
Net income (FY)
-$140.1M
Employees
110
as of 2026-08-09
Market cap
$1.3B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.3M$1.3M2025
Net income-$140.1M-$140.1M2025
Operating income-$135.0M-$135.0M2025
Total assets$146.5M$146.5M2025
Liabilities$138.5M$138.5M2025
Equity$8.0M$8.0M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
License, Non-Affiliate100%
By geography
Not disclosed.
The read
What is Inhibrx Biosciences Inc.’s revenue?
Inhibrx Biosciences Inc. booked $1.3M in FY2025 revenue, growing 550% year over year — faster than 94% of Healthcare companies we track, at a -10773.5% net margin.
Peers · Healthcare
Panbela Therapeutics, Inc.——Electromedical Technologies, Inc.——Global Roundtable Corporation——Bhang Inc.——Certive Solutions Inc.——VistaGen Therapeutics, Inc.46DKey facts
CEOMark Lappe
SectorHealthcare
IndustryBiotechnology
HeadquartersLa Jolla, CA
ExchangeNASDAQ: INBX
Employees110
IPO date2024-05-29
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.